Tibet Pharmaceuticals appoints Hong Yu CEO
This article was originally published in Scrip
Tibet Pharmaceuticals, a developer, manufacturer and marketer of traditional Tibetan medicine in China, has appointed Hong Yu CEO, replacing Taylor Guo who will remain a director of the company. Mr Yu was previously chairman of Tibet Pharmaceuticals.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.